<DOC>
	<DOCNO>NCT00630656</DOCNO>
	<brief_summary>Study evaluate safety potential benefit recombinant human talactoferrin addition standard care severe sepsis .</brief_summary>
	<brief_title>Safety Efficacy Study Recombinant Human Lactoferrin Treat Severe Sepsis</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Lactoferrin</mesh_term>
	<criteria>Age great equal 18 year Onset severe sepsis within previous 24 hour Must receive antibiotic therapy Informed consent form sign patient , legal nextofkin legal guardian Able take medication mouth feed tube Receipt investigational medication within 4 week prior participation study Pregnant breastfeeding Severe congestive heart failure Known severe HIV infection Presence severe burn Patients high dose immunosuppressant Patients whose death consider imminent Patients whose life expectancy concurrent illness le 6 month Severe hypoxic encephalopathy persistent vegetative state Severe liver disease Patient , legal representative patient 's primary physician commit provide full , aggressive life support</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>sepsis</keyword>
	<keyword>talactoferrin</keyword>
	<keyword>lactoferrin</keyword>
	<keyword>recombinant human lactoferrin</keyword>
</DOC>